Session » Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II
-
Abstract Number: 1542
Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis
-
Abstract Number: 1544
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
-
Abstract Number: 1545
Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab
-
Abstract Number: 1546
Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
-
Abstract Number: 1547
Endocrine Co-Morbidities in Patients with Psoriatic Arthritis: A Population-Based Study
-
Abstract Number: 1548
Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial
-
Abstract Number: 1549
The Swedish Early Psoriatic Arhtritis (SWEPSA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities
-
Abstract Number: 1550
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
-
Abstract Number: 1551
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
-
Abstract Number: 1552
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis
-
Abstract Number: 1553
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
-
Abstract Number: 1554
Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
-
Abstract Number: 1555
An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients
-
Abstract Number: 1556
Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program
-
Abstract Number: 1557
Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
-
Abstract Number: 1558
Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response
-
Abstract Number: 1560
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
-
Abstract Number: 1561
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
-
Abstract Number: 1562
Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
-
Abstract Number: 1563
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
-
Abstract Number: 1566
The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis
-
Abstract Number: 1567
The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease
-
Abstract Number: 1568
Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis
-
Abstract Number: 1569
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
-
Abstract Number: 1570
Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities
-
Abstract Number: 1571
Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients with Psoriasis
-
Abstract Number: 1573
Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
-
Abstract Number: 1574
University Students with Psoriatic Nail Changes Have a Greater Number of Tender Enthesial Points Than Those with Normal Nails
-
Abstract Number: 1575
The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis
-
Abstract Number: 1576
Reversal of Damage in Psoriatic Arthritis
-
Abstract Number: 1577
Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
-
Abstract Number: 1578
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
-
Abstract Number: 1579
Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
-
Abstract Number: 1580
Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort
-
Abstract Number: 1581
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
-
Abstract Number: 1582
Cumulative Inflammatory Burden Is Independently Associated with Increased Arterial Stiffness in Patients with Psoriatic Arthritis
-
Abstract Number: 1583
Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp
-
Abstract Number: 1584
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
-
Abstract Number: 1585
Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria
-
Abstract Number: 1586
Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers
-
Abstract Number: 1587
The Economic Impact of Psoriatic Arthritis in Toronto, Ontario
-
Abstract Number: 1588
Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life
-
Abstract Number: 1589
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
-
Abstract Number: 1590
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
-
Abstract Number: 1591
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
-
Abstract Number: 1592
Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis
-
Abstract Number: 1593
Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
-
Abstract Number: 1594
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
-
Abstract Number: 1595
Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States
-
Abstract Number: 1597
Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
-
Abstract Number: 1598
Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
-
Abstract Number: 1599
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
-
Abstract Number: 1600
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
-
Abstract Number: 1601
Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?
-
Abstract Number: 1602
Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis